
## Akihiro Yoshida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7078419/publications.pdf Version: 2024-02-01



Δειμιρο Υορμισλ

#	Article	IF	CITATION
1	Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss. Oncogene, 2022, 41, 2187-2195.	5.9	4
2	Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3. Oncogene, 2021, 40, 292-306.	5.9	13
3	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances, 2019, 5, eaax6352.	10.3	31
4	Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nature Communications, 2019, 10, 1296.	12.8	73
5	A PERK–miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nature Cell Biology, 2018, 20, 104-115.	10.3	86
6	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clinical Cancer Research, 2018, 24, 4201-4214.	7.0	77
7	Effect of bypass kinase pathways on acquired CDK4/6 inhibitor resistance Journal of Clinical Oncology, 2018, 36, 379-379.	1.6	0
8	Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. PLoS ONE, 2017, 12, e0177830.	2.5	17
9	PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. PLoS Genetics, 2016, 12, e1006518.	3.5	41
10	Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Cancer Research, 2016, 76, 2990-3002.	0.9	123
11	Consequence of the tumorâ€associated conversion to cyclin D1b. EMBO Molecular Medicine, 2015, 7, 628-647.	6.9	19